KUALA LUMPUR: The opening of the first central oncology laboratory for clinical trials in Malaysia, Hematogenix is expected to move local pharmaceutical and healthcare industries further up the value chain into research and development (R&D) and related services.
Malaysian Investment Development Authority (Mida) Deputy Chief Executive Officer (Investment Development) Lim Bee Vian said the entry of Hematogenix in Malaysia is also expected to attract more global clinical trials into the country.
Already a subscriber? Log in
Save 30% OFF The Star Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
